Published in Biomedica on April 01, 2014
In Vitro Activity of Ceftaroline against Staphylococcus aureus Isolated in 2012 from Asia-Pacific Countries as Part of the AWARE Surveillance Program. Antimicrob Agents Chemother (2015) 0.86
In Vitro Activity of Ceftaroline against Staphylococcus aureus Isolates Collected in 2012 from Latin American Countries as Part of the AWARE Surveillance Program. Antimicrob Agents Chemother (2015) 0.82
Phage therapy against Enterococcus faecalis in dental root canals. J Oral Microbiol (2016) 0.79
Different Vancomycin-Intermediate Staphylococcus aureus Phenotypes Selected from the Same ST100-hVISA Parental Strain. Microb Drug Resist (2016) 0.75
Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet (1997) 18.24
Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother (1997) 17.36
Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat Rev Microbiol (2009) 10.42
Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev (2001) 9.14
In vitro activity and mechanism of action of A21978C1, a novel cyclic lipopeptide antibiotic. Antimicrob Agents Chemother (1985) 7.83
Genetic analysis of a high-level vancomycin-resistant isolate of Staphylococcus aureus. Science (2003) 7.73
Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med (2003) 7.52
Staphylococcus aureus resistant to vancomycin--United States, 2002. MMWR Morb Mortal Wkly Rep (2002) 7.34
Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet (2001) 5.90
Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50. J Antimicrob Chemother (1998) 4.88
Has the era of untreatable infections arrived? J Antimicrob Chemother (2009) 4.83
Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev (2010) 4.76
The rise of the Enterococcus: beyond vancomycin resistance. Nat Rev Microbiol (2012) 4.64
Antibiotic-resistant bugs in the 21st century--a clinical super-challenge. N Engl J Med (2009) 4.42
The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis (2012) 4.20
Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus. Antimicrob Agents Chemother (2006) 4.19
Stimulus perception in bacterial signal-transducing histidine kinases. Microbiol Mol Biol Rev (2006) 4.12
Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis (2004) 4.09
Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis (2004) 4.06
Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006. Clin Infect Dis (2008) 3.95
Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus. J Clin Microbiol (2003) 3.89
Failures in clinical treatment of Staphylococcus aureus Infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding. Antimicrob Agents Chemother (2007) 3.54
Acquisition of a natural resistance gene renders a clinical strain of methicillin-resistant Staphylococcus aureus resistant to the synthetic antibiotic linezolid. Mol Microbiol (2007) 3.47
Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001. Clin Infect Dis (2003) 3.39
Genetic basis for in vivo daptomycin resistance in enterococci. N Engl J Med (2011) 3.20
Infections caused by Gram-positive bacteria: a review of the global challenge. J Infect (2009) 3.06
Distribution of florfenicol resistance genes fexA and cfr among chloramphenicol-resistant Staphylococcus isolates. Antimicrob Agents Chemother (2006) 2.92
Identification of a plasmid-borne chloramphenicol-florfenicol resistance gene in Staphylococcus sciuri. Antimicrob Agents Chemother (2000) 2.90
First report of cfr-mediated resistance to linezolid in human staphylococcal clinical isolates recovered in the United States. Antimicrob Agents Chemother (2008) 2.63
Methicillin-resistant Staphylococcus aureus strain USA300: origin and epidemiology. J Antimicrob Chemother (2009) 2.58
Development of Daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus. J Clin Microbiol (2005) 2.53
Analysis of cell membrane characteristics of in vitro-selected daptomycin-resistant strains of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (2009) 2.52
Structural transitions as determinants of the action of the calcium-dependent antibiotic daptomycin. Chem Biol (2004) 2.51
Emergence of vancomycin resistant Staphylococcus aureus (VRSA) from a tertiary care hospital from northern part of India. BMC Infect Dis (2006) 2.51
Is it time to replace vancomycin in the treatment of methicillin-resistant Staphylococcus aureus infections? Clin Infect Dis (2013) 2.44
Mode of action of the new antibiotic for Gram-positive pathogens daptomycin: comparison with cationic antimicrobial peptides and lipopeptides. Biochim Biophys Acta (2006) 2.35
Cell envelope stress response in Gram-positive bacteria. FEMS Microbiol Rev (2008) 2.32
Emergence of epidemic multidrug-resistant Enterococcus faecium from animal and commensal strains. MBio (2013) 2.20
Novel ribosomal mutations in Staphylococcus aureus strains identified through selection with the oxazolidinones linezolid and torezolid (TR-700). Antimicrob Agents Chemother (2009) 2.17
Tigecycline. J Antimicrob Chemother (2005) 2.16
Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin. J Clin Microbiol (2006) 2.12
Emergence of resistance to daptomycin during treatment of vancomycin-resistant Enterococcus faecalis infection. Clin Infect Dis (2005) 2.08
Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy. Antimicrob Agents Chemother (2005) 2.05
Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus. Clin Infect Dis (2010) 2.02
In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci. J Antimicrob Chemother (2002) 2.00
16S rRNA mutation associated with tetracycline resistance in a gram-positive bacterium. Antimicrob Agents Chemother (1998) 1.94
The bacterial defensin resistance protein MprF consists of separable domains for lipid lysinylation and antimicrobial peptide repulsion. PLoS Pathog (2009) 1.94
Enhanced expression of dltABCD is associated with the development of daptomycin nonsusceptibility in a clinical endocarditis isolate of Staphylococcus aureus. J Infect Dis (2009) 1.89
Mutations in ribosomal protein L3 are associated with oxazolidinone resistance in staphylococci of clinical origin. Antimicrob Agents Chemother (2009) 1.81
Assessment of linezolid resistance mechanisms among Staphylococcus epidermidis causing bacteraemia in Rome, Italy. J Antimicrob Chemother (2010) 1.80
Emergence and management of drug-resistant enterococcal infections. Expert Rev Anti Infect Ther (2008) 1.80
The oxazolidinone antibiotics perturb the ribosomal peptidyl-transferase center and effect tRNA positioning. Proc Natl Acad Sci U S A (2008) 1.78
Dissemination of methicillin-resistant Staphylococcus aureus USA300 sequence type 8 lineage in Latin America. Clin Infect Dis (2009) 1.77
Daptomycin-mediated reorganization of membrane architecture causes mislocalization of essential cell division proteins. J Bacteriol (2012) 1.75
Genetic basis for daptomycin resistance in enterococci. Antimicrob Agents Chemother (2011) 1.74
Resistance to linezolid caused by modifications at its binding site on the ribosome. Antimicrob Agents Chemother (2011) 1.70
Serial daptomycin selection generates daptomycin-nonsusceptible Staphylococcus aureus strains with a heterogeneous vancomycin-intermediate phenotype. Antimicrob Agents Chemother (2008) 1.63
Nucleotide sequence and organization of the multiresistance plasmid pSCFS1 from Staphylococcus sciuri. J Antimicrob Chemother (2004) 1.60
Counterpoint: Vancomycin and Staphylococcus aureus--an antibiotic enters obsolescence. Clin Infect Dis (2007) 1.59
Whole genome characterization of the mechanisms of daptomycin resistance in clinical and laboratory derived isolates of Staphylococcus aureus. PLoS One (2012) 1.59
An RpoB mutation confers dual heteroresistance to daptomycin and vancomycin in Staphylococcus aureus. Antimicrob Agents Chemother (2010) 1.57
Transcriptional and translational control of the mlr operon, which confers resistance to seven classes of protein synthesis inhibitors. Antimicrob Agents Chemother (2008) 1.57
Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence. J Antimicrob Chemother (2008) 1.56
Linezolid resistance in Staphylococcus aureus: gene dosage effect, stability, fitness costs, and cross-resistances. Antimicrob Agents Chemother (2008) 1.51
The LiaFSR system regulates the cell envelope stress response in Streptococcus mutans. J Bacteriol (2009) 1.50
Identification and characterization of a vancomycin-resistant Staphylococcus aureus isolated from Kolkata (South Asia). J Med Microbiol (2008) 1.50
Limitations of vancomycin in the management of resistant staphylococcal infections. Clin Infect Dis (2007) 1.49
MRSA USA300 clone and VREF--a U.S.-Colombian connection? N Engl J Med (2008) 1.44
Analysis of clonality and antibiotic resistance among early clinical isolates of Enterococcus faecium in the United States. J Infect Dis (2009) 1.42
Emergence of high-level vancomycin-resistant Staphylococcus aureus in the Imam Khomeini Hospital in Tehran. Med Princ Pract (2008) 1.42
fexA, a novel Staphylococcus lentus gene encoding resistance to florfenicol and chloramphenicol. Antimicrob Agents Chemother (2004) 1.42
Correlation between mutations in liaFSR of Enterococcus faecium and MIC of daptomycin: revisiting daptomycin breakpoints. Antimicrob Agents Chemother (2012) 1.41
Ceftaroline: a novel broad-spectrum cephalosporin with activity against meticillin-resistant Staphylococcus aureus. Drugs (2009) 1.41
Critical shortage of new antibiotics in development against multidrug-resistant bacteria-Time to react is now. Drug Resist Updat (2011) 1.40
Identification and characterization of the multidrug resistance gene cfr in a Panton-Valentine leukocidin-positive sequence type 8 methicillin-resistant Staphylococcus aureus IVa (USA300) isolate. Antimicrob Agents Chemother (2010) 1.40
Summary of ceftaroline fosamil clinical trial studies and clinical safety. Clin Infect Dis (2012) 1.38
Linezolid (ZYVOX), the first member of a completely new class of antibacterial agents for treatment of serious gram-positive infections. J Med Chem (2008) 1.36
Daptomycin-resistant Enterococcus faecalis diverts the antibiotic molecule from the division septum and remodels cell membrane phospholipids. MBio (2013) 1.35
Broad-spectrum antimicrobial peptide resistance by MprF-mediated aminoacylation and flipping of phospholipids. Mol Microbiol (2011) 1.34
Transferable plasmid-mediated resistance to linezolid due to cfr in a human clinical isolate of Enterococcus faecalis. Antimicrob Agents Chemother (2012) 1.31
Alternatives to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis (2007) 1.30
Clinical and microbiological aspects of linezolid resistance mediated by the cfr gene encoding a 23S rRNA methyltransferase. J Clin Microbiol (2008) 1.30
VraSR two-component regulatory system contributes to mprF-mediated decreased susceptibility to daptomycin in in vivo-selected clinical strains of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (2011) 1.28
Biosynthesis of cardiolipin from phosphatidylglycerol in Staphylococcus aureus. J Bacteriol (1972) 1.28
Development of decreased susceptibility to daptomycin and vancomycin in a Staphylococcus aureus strain during prolonged therapy. J Antimicrob Chemother (2006) 1.27
Contribution of selected gene mutations to resistance in clinical isolates of vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother (2012) 1.27
Ceftaroline: a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus. Clin Infect Dis (2011) 1.25
Whole-genome analysis of a daptomycin-susceptible enterococcus faecium strain and its daptomycin-resistant variant arising during therapy. Antimicrob Agents Chemother (2012) 1.25
In vitro selection and characterization of ceftobiprole-resistant methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (2008) 1.21
Antimicrobial susceptibility of 22746 pathogens from Canadian hospitals: results of the CANWARD 2007-11 study. J Antimicrob Chemother (2013) 1.20
Bad bugs, no drugs: no ESCAPE revisited. Clin Infect Dis (2009) 1.20
Elevated linezolid resistance in clinical cfr-positive Staphylococcus aureus isolates is associated with co-occurring mutations in ribosomal protein L3. Antimicrob Agents Chemother (2010) 1.20
Pharmacokinetics and pharmacodynamics of ceftobiprole, an anti-MRSA cephalosporin with broad-spectrum activity. Clin Pharmacokinet (2008) 1.19
Genotypic and phenotypic evaluation of the evolution of high-level daptomycin nonsusceptibility in vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother (2012) 1.18
Clinical experience with daptomycin in Europe: the first 2.5 years. J Antimicrob Chemother (2011) 1.17
LEADER surveillance program results for 2010: an activity and spectrum analysis of linezolid using 6801 clinical isolates from the United States (61 medical centers). Diagn Microbiol Infect Dis (2012) 1.16
Oligomerization of daptomycin on membranes. Biochim Biophys Acta (2011) 1.16
Tetracycline compounds with non-antimicrobial organ protective properties: possible mechanisms of action. Pharmacol Res (2010) 1.15